Multidrug-resistant tuberculosis in Europe, 2010-2011

Gunar Günther, Frank van Leth, Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Davilovits, Martin Dedicoat, Raquel Duarte, Gina Gualano, Heinke Kunst, Wiel de Lange, Vaira Leimane, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle & 12 andre Veronika Polcová, Emanuele Pontali, Christina Popa, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Piret Viiklepp, Christoph Lange, TBNET, Åse Bengård Andersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

53 Downloads (Pure)

Resumé

Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

OriginalsprogEngelsk
TidsskriftEmerging Infectious Diseases (Print Edition)
Vol/bind21
Udgave nummer3
Sider (fra-til)409-16
Antal sider8
ISSN1080-6040
DOI
StatusUdgivet - mar. 2015

Fingeraftryk

Mycobacterium tuberculosis
Pharmaceutical Preparations
Pyrazinamide
Drug Resistance

Citer dette

Günther, G., van Leth, F., Alexandru, S., Altet, N., Avsar, K., Bang, D., ... Andersen, Å. B. (2015). Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerging Infectious Diseases (Print Edition), 21(3), 409-16. https://doi.org/10.3201/eid2103.141343
Günther, Gunar ; van Leth, Frank ; Alexandru, Sofia ; Altet, Neus ; Avsar, Korkut ; Bang, Didi ; Barbuta, Raisa ; Bothamley, Graham ; Ciobanu, Ana ; Crudu, Valeriu ; Davilovits, Manfred ; Dedicoat, Martin ; Duarte, Raquel ; Gualano, Gina ; Kunst, Heinke ; de Lange, Wiel ; Leimane, Vaira ; Magis-Escurra, Cecile ; McLaughlin, Anne-Marie ; Muylle, Inge ; Polcová, Veronika ; Pontali, Emanuele ; Popa, Christina ; Rumetshofer, Rudolf ; Skrahina, Alena ; Solodovnikova, Varvara ; Spinu, Victor ; Tiberi, Simon ; Viiklepp, Piret ; Lange, Christoph ; TBNET ; Andersen, Åse Bengård. / Multidrug-resistant tuberculosis in Europe, 2010-2011. I: Emerging Infectious Diseases (Print Edition). 2015 ; Bind 21, Nr. 3. s. 409-16.
@article{d3d33663efbf4814a0fa5632dc694584,
title = "Multidrug-resistant tuberculosis in Europe, 2010-2011",
abstract = "Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4{\%} of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7{\%} of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1{\%} were resistant to ≥1 second-line drug, 26.6{\%} were resistant to second-line injectable drugs, 17.6{\%} were resistant to fluoroquinolones, and 6.8{\%} were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.",
keywords = "Adult, Antitubercular Agents, Comorbidity, Cross-Sectional Studies, Europe, Female, History, 21st Century, Humans, Incidence, Male, Microbial Sensitivity Tests, Middle Aged, Mycobacterium tuberculosis, Population Surveillance, Risk Factors, Tuberculosis, Multidrug-Resistant",
author = "Gunar G{\"u}nther and {van Leth}, Frank and Sofia Alexandru and Neus Altet and Korkut Avsar and Didi Bang and Raisa Barbuta and Graham Bothamley and Ana Ciobanu and Valeriu Crudu and Manfred Davilovits and Martin Dedicoat and Raquel Duarte and Gina Gualano and Heinke Kunst and {de Lange}, Wiel and Vaira Leimane and Cecile Magis-Escurra and Anne-Marie McLaughlin and Inge Muylle and Veronika Polcov{\'a} and Emanuele Pontali and Christina Popa and Rudolf Rumetshofer and Alena Skrahina and Varvara Solodovnikova and Victor Spinu and Simon Tiberi and Piret Viiklepp and Christoph Lange and TBNET and Andersen, {{\AA}se Beng{\aa}rd}",
year = "2015",
month = "3",
doi = "10.3201/eid2103.141343",
language = "English",
volume = "21",
pages = "409--16",
journal = "Emerging Infectious Diseases (Print Edition)",
issn = "1080-6040",
publisher = "U.S. Department of Health and Human Services Centers for Disease Control and Prevention",
number = "3",

}

Günther, G, van Leth, F, Alexandru, S, Altet, N, Avsar, K, Bang, D, Barbuta, R, Bothamley, G, Ciobanu, A, Crudu, V, Davilovits, M, Dedicoat, M, Duarte, R, Gualano, G, Kunst, H, de Lange, W, Leimane, V, Magis-Escurra, C, McLaughlin, A-M, Muylle, I, Polcová, V, Pontali, E, Popa, C, Rumetshofer, R, Skrahina, A, Solodovnikova, V, Spinu, V, Tiberi, S, Viiklepp, P, Lange, C, TBNET & Andersen, ÅB 2015, 'Multidrug-resistant tuberculosis in Europe, 2010-2011', Emerging Infectious Diseases (Print Edition), bind 21, nr. 3, s. 409-16. https://doi.org/10.3201/eid2103.141343

Multidrug-resistant tuberculosis in Europe, 2010-2011. / Günther, Gunar; van Leth, Frank; Alexandru, Sofia; Altet, Neus; Avsar, Korkut; Bang, Didi; Barbuta, Raisa; Bothamley, Graham; Ciobanu, Ana; Crudu, Valeriu; Davilovits, Manfred; Dedicoat, Martin; Duarte, Raquel; Gualano, Gina; Kunst, Heinke; de Lange, Wiel; Leimane, Vaira; Magis-Escurra, Cecile; McLaughlin, Anne-Marie; Muylle, Inge; Polcová, Veronika; Pontali, Emanuele; Popa, Christina; Rumetshofer, Rudolf; Skrahina, Alena; Solodovnikova, Varvara; Spinu, Victor; Tiberi, Simon; Viiklepp, Piret; Lange, Christoph; TBNET; Andersen, Åse Bengård (Medlem af forfattergruppering).

I: Emerging Infectious Diseases (Print Edition), Bind 21, Nr. 3, 03.2015, s. 409-16.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Multidrug-resistant tuberculosis in Europe, 2010-2011

AU - Günther, Gunar

AU - van Leth, Frank

AU - Alexandru, Sofia

AU - Altet, Neus

AU - Avsar, Korkut

AU - Bang, Didi

AU - Barbuta, Raisa

AU - Bothamley, Graham

AU - Ciobanu, Ana

AU - Crudu, Valeriu

AU - Davilovits, Manfred

AU - Dedicoat, Martin

AU - Duarte, Raquel

AU - Gualano, Gina

AU - Kunst, Heinke

AU - de Lange, Wiel

AU - Leimane, Vaira

AU - Magis-Escurra, Cecile

AU - McLaughlin, Anne-Marie

AU - Muylle, Inge

AU - Polcová, Veronika

AU - Pontali, Emanuele

AU - Popa, Christina

AU - Rumetshofer, Rudolf

AU - Skrahina, Alena

AU - Solodovnikova, Varvara

AU - Spinu, Victor

AU - Tiberi, Simon

AU - Viiklepp, Piret

AU - Lange, Christoph

AU - TBNET

A2 - Andersen, Åse Bengård

PY - 2015/3

Y1 - 2015/3

N2 - Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

AB - Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

KW - Adult

KW - Antitubercular Agents

KW - Comorbidity

KW - Cross-Sectional Studies

KW - Europe

KW - Female

KW - History, 21st Century

KW - Humans

KW - Incidence

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Mycobacterium tuberculosis

KW - Population Surveillance

KW - Risk Factors

KW - Tuberculosis, Multidrug-Resistant

U2 - 10.3201/eid2103.141343

DO - 10.3201/eid2103.141343

M3 - Journal article

VL - 21

SP - 409

EP - 416

JO - Emerging Infectious Diseases (Print Edition)

JF - Emerging Infectious Diseases (Print Edition)

SN - 1080-6040

IS - 3

ER -

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerging Infectious Diseases (Print Edition). 2015 mar;21(3):409-16. https://doi.org/10.3201/eid2103.141343